GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GW Pharmaceuticals PLC (NAS:GWPH) » Definitions » Equity-to-Asset

GW Pharmaceuticals (GW Pharmaceuticals) Equity-to-Asset : 0.79 (As of Mar. 2021)


View and export this data going back to 2013. Start your Free Trial

What is GW Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. GW Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2021 was $736.4 Mil. GW Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2021 was $934.3 Mil. Therefore, GW Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Mar. 2021 was 0.79.

The historical rank and industry rank for GW Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

GWPH' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.07   Med: 0.81   Max: 0.91
Current: 0.79

During the past 13 years, the highest Equity to Asset Ratio of GW Pharmaceuticals was 0.91. The lowest was -0.07. And the median was 0.81.

GWPH's Equity-to-Asset is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.59 vs GWPH: 0.79

GW Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for GW Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GW Pharmaceuticals Equity-to-Asset Chart

GW Pharmaceuticals Annual Data
Trend Sep11 Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Dec19 Dec20
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.88 0.86 0.85 0.82 0.79

GW Pharmaceuticals Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.84 0.82 0.81 0.79 0.79

Competitive Comparison of GW Pharmaceuticals's Equity-to-Asset

For the Drug Manufacturers - General subindustry, GW Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GW Pharmaceuticals's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GW Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where GW Pharmaceuticals's Equity-to-Asset falls into.



GW Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

GW Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Equity to Asset (A: Dec. 2020 )=Total Stockholders Equity/Total Assets
=741.09/939.511
=0.79

GW Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Mar. 2021 is calculated as

Equity to Asset (Q: Mar. 2021 )=Total Stockholders Equity/Total Assets
=736.373/934.343
=0.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GW Pharmaceuticals  (NAS:GWPH) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


GW Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of GW Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


GW Pharmaceuticals (GW Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Sovereign House, Chivers Way, Vision Park, Histon, Cambridge, GBR, CB24 9BZ
GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.
Executives
Douglas B. Snyder officer: Chief Legal Officer SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB249BZ
Volker Knappertz officer: Chief Medical Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB249BZ
Cabot Brown director SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ
Adam D. George officer: Secretary SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ
Guy Geoffrey W Dr director, officer: Executive Chairman ETHICAL HOLDINGS PLC CORPUS CHRISTI HOUSE 9 WEST STREET GODMANCHESTER CAMBRIDGESHIRE PE18 A1
Christopher J. Tovey officer: Chief Operating Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Justin D. Gover director, officer: Chief Executive Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
James Noble director C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Alicia Secor director 33 HAYDEN AVE., LEXINGTON MA 02421
Darren S Cline officer: U.S. Chief Commercial Officer 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
William A. Waldegrave director SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ
Scott M. Giacobello officer: Chief Financial Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Julian S Gangolli officer: President, North America 4955 BASELINE AVENUE, SANTA YNEZ CA 93460

GW Pharmaceuticals (GW Pharmaceuticals) Headlines

From GuruFocus